Yaupon Therapeutics, Inc

yaupon therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. the company’s lead product candidate, clearazide™, a proprietary topical formulation of nitrogen mustard (nm), is being evaluated in a pivotal phase ii/iii trial under a special protocol assessment (spa) with the fda for the treatment of early-stage cutaneous t-cell lymphoma – mycosis fungoides (ctcl-mf). the fda has granted clearazide™ fast-track designation and orphan drug status.